Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Declines By 46.6%

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a large decrease in short interest in July. As of July 31st, there was short interest totaling 187,000 shares, adecreaseof46.6% from the July 15th total of 350,400 shares. Based on an average daily trading volume, of 282,900 shares, the days-to-cover ratio is presently 0.7 days. Based on an average daily trading volume, of 282,900 shares, the days-to-cover ratio is presently 0.7 days.

Astellas Pharma Stock Up 1.0%

Astellas Pharma stock opened at $11.29 on Monday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.13 and a quick ratio of 0.85. Astellas Pharma has a 1-year low of $8.37 and a 1-year high of $13.14. The company’s 50-day moving average is $9.96 and its 200 day moving average is $9.74.

Astellas Pharma (OTCMKTS:ALPMY) last issued its earnings results on Wednesday, July 30th. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.26. The business had revenue of $3.41 billion for the quarter, compared to the consensus estimate of $3.20 billion. Astellas Pharma had a net margin of 4.34% and a return on equity of 19.76%. Equities research analysts anticipate that Astellas Pharma will post 0.42 earnings per share for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.